Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy

Expert Opinion on Investigational Drugs

Volumn 23, Issue 5, 2014, Pages 599-610

  Criscitiello, Carmen ^a   Gelao, Lucia ^a   Viale, Giulia ^a   Esposito, Angela ^a   Curigliano, Giuseppe ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Breast cancer; Platelet derived growth factor receptors; Sunitinib; Tyrosine kinase inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; CAPECITABINE; DOCETAXEL; DOVITINIB; DOXORUBICIN; FLUOROURACIL; IMATINIB; LAPATINIB; LINIFANIB; ORANTINIB; PACLITAXEL; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR C; PLATELET DERIVED GROWTH FACTOR D; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TIVOZANIB; UNCLASSIFIED DRUG; NEW DRUG; PROTEIN KINASE INHIBITOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BIOLOGICAL ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER THERAPY; GENOMICS; HUMAN; METASTASIS; MONOTHERAPY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHYSIOLOGICAL PROCESS; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIAL (TOPIC); ENZYMOLOGY; FEMALE; METABOLISM; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; FEMALE; HUMANS; PROTEIN KINASE INHIBITORS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA;

EID: 84898423106     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.895323     Document Type: Review

References (84)

1. Hubbard SR. Juxtamembrane autoinhibition in receptor tyrosine kinas es. Nat Rev Mol Cell Biol 2004;5:464-71
2. Eskens FA. Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer 2004;90:1-7
3. McCarty MF, Liu W, Fan F, et al. Promises and pitfalls of anti-Angiogenic therapy in clinical trials. Trends Mol Med 2003;9:53-8
4. Tallquist M, Kazlauskas A. PDGF signaling in cells and mice. Cytokine Growth Factor Rev 2004;15:205-13
5. Wells A, Grandis Jr. Phospholipase C-gamma1 in tumor progression. Clin Exp Metastasis 2003;20:285-90
6. Arteaga CL, Johnson MD, Todderud G, et al. Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas. Proc Natl Acad Sci USA 1991;88:10435-9
7. Donovan J, Shiwen X, Norman J, Abraham D. Platelet-derived growth factor alpha and beta receptors have overlapping functional activities towards fibroblasts. Fibrogenesis Tissue Repair 2013;6:10
8. Nister M, Claesson-Welsh L, Eriksson A, et al. Differential expression of plateletderived growth factor receptors in human malignant glioma cell lines. J Biol Chem 1991;266:16755-63
9. Walker RA. The complexities of breast cancer desmoplasia. Breast Cancer Res 2001;3:143-5
10. Lev DC, Kim SJ, Onn A, et al. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice. Clin Cancer Res 2005;11:306-14
11. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008;22:1276-312
12. Ostman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 2004;15:275-86
13. Ahmad A, Wang Z, Kong D, et al. Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-kappaB signaling pathways. Breast Cancer Res Treat 2011;126:15-25
14. Wang Z, Li Y, Kong D, Sarkar FH. The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness. Curr Drug Targets 2010;11:745-51
15. Hurst NJ Jr, Najy AJ, Ustach CV, et al. Platelet-derived growth factor-C (PDGFC) activation by serine proteases: Implications for breast cancer progression. Biochem J 2012;441:909-18
16. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004;432:332-7
17. George D. Platelet-derived growth factor receptors: A therapeutic target in solid tumors. Semin Oncol 2001;28:27-33
18. Nakamura Y, Tanaka F, Yoshikawa Y, et al. PDGF-BB is a novel prognostic factor in colorectal cancer. Ann Surg Oncol 2008;15:2129-36
19. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10
20. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002;347:481-7
21. Jechlinger M, Sommer A, Moriggl R, et al. Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest 2006;116:1561-70
22. Yu J, Ustach C, Kim HR. Platelet-derived growth factor signaling and human cancer. J Biochem Mol Biol 2003;36:49-59
23. Vrekoussis T, Stathopoulos EN, Kafousi M, et al. Expression of endothelial PDGF receptors alpha and beta in breast cancer: Up-regulation of endothelial PDGF receptor beta. Oncol Rep 2007;17:1115-19
24. Song S, Ewald AJ, Stallcup W, et al. PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 2005;7:870-9
25. Wang Z, Kong D, Banerjee S, et al. Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-kappaB signaling. Cancer Res 2007;67:11377-85
26. Sasaki T, Arai H, Beppu T, Ogasawara K. Detection of gene amplification and deletion in high-grade gliomas using a genome DNA microarray (GenoSensor Array 300). Brain Tumor Pathol 2003;20:59-63
27. Hunter SB, Brat DJ, Olson JJ, et al. Alterations in molecular pathways of diffusely infiltrating glial neoplasms: Application to tumor classification and anti-Tumor therapy (Review). Int J Oncol 2003;23:857-69
28. Smith JS, Wang XY, Qian J, et al. Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features. J Neuropathol Exp Neurol 2000;59:495-503
29. Zhao J, Roth J, Bode-Lesniewska B, et al. Combined comparative genomic hybridization and genomic microarray for detection of gene amplifications in pulmonary artery intimal sarcomas and adrenocortical tumors. Genes Chromosomes Cancer 2002;34:48-57
30. Daigo Y, Chin SF, Gorringe KL, et al. Degenerate oligonucleotide primedpolymerase chain reaction-based array comparative genomic hybridization for extensive amplicon profiling of breast cancers : A new approach for the molecular analysis of paraffin-embedded cancer tissue. Am J Pathol 2001;158:1623-31
31. Carvalho I, Milanezi F, Martins A, et al. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res 2005;7:R788-95
32. Carvalho S, e Silva AO, Milanezi F, et al. c-KIT and PDGFRA in breast phyllodes tumours: Overexpression without mutations? J Clin Pathol 2004;57:1075-9
33. Sihto H, Sarlomo-Rikala M, Tynninen O, et al. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol 2005;23:49-57
34. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994;77:307-16
35. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-14
36. Seymour L, Dajee D, Bezwoda WR. Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer. Breast Cancer Res Treat 1993;26:247-52
37. Thommen R, Humar R, Misevic G, et al. PDGF-BB increases endothelial migration on cord movements during angiogenesis in vitro. J Cell Biochem 1997;64:403-13
38. Wang D, Huang HJ, Kazlauskas A, Cavenee WK. Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res 1999;59:1464-72
39. Abramsson A, Lindblom P, Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 2003;112:1142-51
40. Guo P, Hu B, Gu W, et al. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol 2003;162:1083-93
41. Pietras K, Pahler J, Bergers G, Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 2008;5:e19
42. Crawford Y, Kasman I, Yu L, et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009;15:21-34
43. Ehnman M, Ostman A. Therapeutic targeting of platelet-derived growth factor receptors in solid tumors. Expert Opin Investig Drugs 2014;23(2):211-26
44. Paulsson J, Sjoblom T, Micke P, et al. Prognostic significance of stromal platelet-derived growth factor betareceptor expression in human breast cancer. Am J Pathol 2009;175:334-41
45. Laschke MW, Elitzsch A, Vollmar B, et al. Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and plateletderived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions. Hum Reprod 2006;21:262-8
46. Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003;2:1011-21
47. Limvorasak S, Posadas EM. Pazopanib: Therapeutic developments. Expert Opin Pharmacother 2009;10:3091-102
48. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6:2012-21
49. Gril B, Palmieri D, Qian Y, et al. Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis. Clin Cancer Res 2011;17:142-53
50. Gril B, Palmieri D, Qian Y, et al. Pazopanib inhibits the activation of PDGFRbeta-expressing astrocytes in the brain metastatic microenvironment of breast cancer cells. Am J Pathol 2013;182:2368-79
51. Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009;15:4220-7
52. Tan AR, Dowlati A, Jones SF, et al. Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. Oncologist 2010;15:1253-61
53. de Jonge MJ, Hamberg P, Verweij J, et al. Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. Invest New Drugs 2013;31:751-9
54. Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7:3129-40
55. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109
56. Merz M, Komljenovic D, Zwick S, et al. Sorafenib tosylate and paclitaxel induce anti-Angiogenic, anti-Tumour and antiresorptive effects in experimental breast cancer bone metastases. Eur J Cancer 2011;47:277-86
57. Asahina H, Tamura Y, Nokihara H, et al. An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors. Cancer Chemother Pharmacol 2012;69:1477-86
58. A Study of Linifanib (ABT-869) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC). Available from: Http://clinicaltrials.gov/
59. Laird AD, Vajkoczy P, Shawver LK, et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000;60:4152-60
60. Huang X, Wong MK, Yi H, et al. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein. Cancer Res 2002;62:5727-35
61. De Luca A, Normanno N. Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors. IDrugs 2010;13:636-45
62. Andre F, Bachelot T, Campone M, et al. Targeting FGFR with dovitinib (TKI258): Preclinical and clinical data in breast cancer. Clin Cancer Res 2013;19:3693-702
63. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after shortterm treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-9
64. Cooke VG, LeBleu VS, Keskin D, et al. Pericyte depletion results in hypoxia-Associated epithelial-To-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 2012;21:66-81
65. Welti JC, Powles T, Foo S, et al. Contrasting effects of sunitinib within in vivo models of metastasis. Angiogenesis 2012;15:623-41
66. Chung AS, Kowanetz M, Wu X, et al. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. J Pathol 2012;227:404-16
67. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008;26:1810-16
68. Yardley DA, Dees EC, Myers SD, et al. Phase II open-label study of sunitinib in patients with advanced breast cancer. Breast Cancer Res Treat 2012;136:759-67
69. Bergh J, Mariani G, Cardoso F, et al. Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. Breast 2012;21:507-13
70. Kozloff M, Chuang E, Starr A, et al. An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Ann Oncol 2010;21:1436-41
71. Curigliano G, Pivot X, Cortes J, et al. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer. Breast 2013;22:650-6
72. Taylor SK, Chia S, Dent S, et al. A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: A trial of the Princess Margaret Hospital phase II consortium. Oncologist 2010;15:810-18
73. Johnston SR, Gomez H, Stemmer SM, et al. A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer. Breast Cancer Res Treat 2013;137:755-66
74. Gradishar WJ, Kaklamani V, Sahoo TP, et al. A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. Eur J Cancer 2013;49:312-22
75. Baselga J, Segalla JG, Roche H, et al. Sorafenib in combination with capecitabine: An oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol 2012;30:1484-91
76. Baselga J, Costa F, Gomez H, et al. A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast Cancer (the RESILIENCE study): Study protocol for a randomized controlled trial. Trials 2013;14:228
77. Cristofanilli M, Morandi P, Krishnamurthy S, et al. Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: Clinical activity and biological correlations. Ann Oncol 2008;19:1713-19
78. Rugo HS, Stopeck AT, Joy AA, et al. Randomized, placebo-controlled, doubleblind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol 2011;29:2459-65
79. Mayer EL, Scheulen ME, Beckman J, et al. A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer. Breast Cancer Res Treat 2013;140:331-9
80. Weigel MT, Ghazoui Z, Dunbier A, et al. Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer. Breast Cancer Res 2012;14:R78
81. Weigel MT, Banerjee S, Arnedos M, et al. Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer. Ann Oncol 2013;24:126-33
82. Chow LW, Yip AY, Loo WT, Toi M. Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer. Cancer Lett 2008;262:232-8
83. Arun B, Murray JL, Walters R. The combination of letrozole and imatinib mesylate for metastatic breast cancer [abstract 214]. San Antonio Breast Cancer Symposium, San Antonio, TX; 2009
84. Santarpia L, Qi Y, Stemke-Hale K, et al. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat 2012;134:333-43